Short Interest in Soligenix, Inc. (NASDAQ:SNGX) Drops By 12.1%

Soligenix, Inc. (NASDAQ:SNGX) was the recipient of a large decline in short interest in February. As of February 15th, there was short interest totalling 106,400 shares, a decline of 12.1% from the January 31st total of 121,000 shares. Currently, 4.2% of the company’s stock are sold short. Based on an average trading volume of 220,800 shares, the short-interest ratio is presently 0.5 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Soligenix stock. Stephens Inc. AR acquired a new position in shares of Soligenix, Inc. (NASDAQ:SNGX) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 46,262 shares of the biopharmaceutical company’s stock, valued at approximately $184,000. Stephens Inc. AR owned about 4.69% of Soligenix at the end of the most recent reporting period. 3.60% of the stock is owned by hedge funds and other institutional investors.

Soligenix Stock Up 1.4 %

NASDAQ:SNGX opened at $2.23 on Thursday. Soligenix has a twelve month low of $1.83 and a twelve month high of $14.92. The company has a market cap of $5.60 million, a P/E ratio of -0.30 and a beta of 1.83. The business has a 50 day moving average price of $2.56 and a two-hundred day moving average price of $3.26.

About Soligenix

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.